🦊/Investors

New Alliance Capital

Private equity

Shanghai · Seed–Late Stage · 25 people tracked

Find your way into New Alliance Capital

397 people in our graph share verified history with the New Alliance Capital team — schools, employers, funds. One of them is your warm intro.

John Keiltyunlockedknows Jun Shi · together at Brandeis University (overlapped)
×6knows the team · via Brandeis University
×2knows the team · via Columbia University
knows the team · via Shanghai Jiao Tong University
knows the team · via Southwestern University of Finance and Economics
knows the team · via Carnegie Mellon University - Tepper School of Business
Fox Verdict
Sign up to see your fit

Investment thesis

New Alliance Capital invests across information technology, healthcare, and future/frontier technology, backing companies at early, growth, and mature stages. Rooted in hard-tech industries, the firm emphasizes value-added services, drawing on its team's experience in state-enterprise restructuring, private venture investing, and multinational localization. It leverages industry and research resources to provide financial and strategic support to Chinese companies and entrepreneurs, aiming to nurture industry leaders with international competitiveness. The firm has completed over 150 investments, with more than 30 portfolio companies listed publicly, and manages multiple funds with cumulative assets exceeding RMB 17 billion.

Source: firm website, verified Aug 3, 2026.

Stage
Seed–Late Stage
HQ
Shanghai, CN
Instruments
Equity
Founded
2008
AUM
$2.4B
Tracked investments
2

Team · 25 people

from the firm's website & public directories
Liefeng Qu· Chairman and Founding Partner
Mengfei Xiongin
Miao Liin
Nan Zhangin
Nan Zhengin
Yan Zhouin

What they invest in

from 2 of 2 portfolio companies

Biotech ×2AI & Machine Learning ×1Deep Tech ×1Healthtech ×1

HQs:United States×1

Investments · 2 tracked

founders shown can be your intro path
Arnatar Therapeuticsarnatar.comin𝕏

Arnatar develops a next-generation RNA discovery platform called DARGER that combines gene silencing and gene upregulation technologies for oligonucleotide therapeutics.

AI & Machine LearningBiotechDeep Tech

Dr. Xuehai Liang(Founder)Dr. Yanfeng Wang(Founder & Chief Operating Officer)

Co-investors3E Bioventures CapitalF-Prime CapitalApricot CapitalEight Roads VenturesGaorong VenturesLegend Star

Eccogeneeccogene.cominJun 2023

Eccogene is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for cardiometabolic and inflammatory conditions, including obesity, type 2 diabetes, and liver disease.

BiotechHealthtechCambridge, US

Jingye Zhou(Founder)in

Co-investorsDelos Capital

Portfolio news

latest coverage across their companies

Frequently asked questions

What stage does New Alliance Capital invest at?
New Alliance Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What sectors does New Alliance Capital focus on?
New Alliance Capital focuses on AI & Machine Learning, Biotech, Consumer, Data & Infrastructure, Deep Tech, Digital Health, Energy, Enterprise Software, Fintech, Healthtech, Media & Entertainment, Medical Devices, New Materials, Retail Tech, SaaS.
Where is New Alliance Capital located?
New Alliance Capital is headquartered in Shanghai, CN.

Similar investors

Featured in lists